Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (350841)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jul 15, 2024

Later deadlines: Aug 19, 2024, Jan 15, 2025, Apr 18, 2025, Jul 15, 2025, Aug 18, 2025, Jan 15, 2026, Apr 17, 2026, Jul 15, 2026, Aug 18, 2026

Grant amount: Up to US $5,500,000

Fields of work: Neuroscience Pharmacology

Applicant type: For-Profit Business

Funding uses: Research

Location of project: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico Show all

Location of residency: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico Show all

Overview:

NOTE: The following deadlines apply to standard grant applications (due by 5:00 pm  local time of applicant organization. Optional but encouraged Letters of Intent are due thirty days prior to application due date.


  • February 9, 2024
  • July 15, 2024
  • January 15, 2025
  • July 15, 2025
  • January 15, 2026
  • July 15, 2026
The following deadlines apply to AIDS-related grant applications (due by 5:00 pm local time of applicant organization. Optional but encouraged Letters of Intent are due thirty days prior to application due date.

  • April 18, 2024
  • August 19, 2024
  • April 18, 2025
  • August 18, 2025
  • April 17, 2026
  • August 18, 2026
Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

Your history with this funder
0
SAVED OPPORTUNITIES
No saved opportunities from this funder yet
FUNDER NOTES
Save this opportunity to add notes...
CONTACTS
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed November 14, 2023 and last updated November 14, 2023